Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 5, 2012, Pages 485-493

  Bakhai, Ameet ^a,c   Rigney, Una ^b   Hollis, Samuel ^b   Emmas, Cathy ^b  

^a BARNET HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c AMORE Health Ltd   (United Kingdom)

Author keywords

Concomitant administration; Cytochrome p450 3a4 inhibitors; General practice research database; Statins

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; DARUNAVIR; DILTIAZEM; ERYTHROMYCIN; EZETIMIBE PLUS SIMVASTATIN; FLUCONAZOLE; FLUINDOSTATIN; FOSAMPRENAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MIBEFRADIL; NELFINAVIR; OXIDOREDUCTASE INHIBITOR; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; TELITHROMYCIN; TIPRANAVIR; UNINDEXED DRUG; VERAPAMIL;

ADVERSE DRUG REACTION; AGED; ARTICLE; COHORT ANALYSIS; DRUG EXPOSURE; DRUG INTERACTION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REFERENCE DATABASE; RETROSPECTIVE STUDY; UNITED KINGDOM;

AGE FACTORS; AGED; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DATABASES, FACTUAL; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PYRROLES; RETROSPECTIVE STUDIES; SIMVASTATIN;

EID: 84859994076     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2308     Document Type: Article

References (31)

1. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97(suppl): 27C-31C.
2. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-1107.
3. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; 97(suppl): 61C-68C.
4. Ronaldson KJ, O'Shea JM, Boyd IW. Risk factors for rhabdomylosis with simvastatin and atorvastatin. Drug Saf 2006; 29: 1061-1067.
5. CG67 Lipid modification: NICE guideline (full). Issue date May 2008 (reissued March 2010). section 3.1.10 & 3.1.14. (accessed 3/11/2010)
6. Acharjee S, Welty FK. Atorvastatin and cardiovascular risk in the elderly--patient considerations. Clin Interv Aging 2008; 3(2): 299-314.
7. MHRA Drug Safety Update, Vol 1, Issue 6, January 2008.
8. Ming EE, Davidson, MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2008; 2: 453-463.
9. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28: 263-275.
10. Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Br J Clin Pharmacol 2009; 67(2): 234-241.
11. García-Rodríguez LA, Massó-González EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100, 000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008 Oct; 17(10): 943-952.
12. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008 Sep; 29(17): 2083-2091.
13. Worz R, Bottorf M. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Expert Opin Pharmacother 2001; 2: 1119-1127.
14. Flockhart Drug Interaction Table. Last updated Jan 12, 2009. Available at: Acessed, April 2009.
15. Crestor_ Summary_ of_ Product_ Characteristics. (accessed 1/07/09)
16. Lipitor_ Summary_ of_ Product_ Characteristics._ (accessed 1/07/09)
17. Lipostat_ Summary_ of_ Product_ Characteristics._ (accessed 1/07/09)
18. Zocor_ Summary_ of_ Product_ Characteristics._ (accessed 1/07/09)
19. Lescol_ Summary_ of_ Product_ Characteristics._ (accessed 1/07/09)
20. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type 2a or 2b hypercholesterolemia. Am J Cardiol 2002; 89: 268-275.
21. Brown WV, Bays HE, Hassman DR, et al. for the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomised, double-blind, 52week trail. Am Heart J 2002; 144: 1036-1043.
22. CG67 Lipid modification: NICE guideline. Issue date May 2008 (reissued March 2010). (accessed 3/7/2010)
23. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006; 97(8A): 52-60.
24. Molden E, Skovlund E, Braathen P. Risk management of simvastain or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf 2008; 31(7): 587-596.
25. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681.
26. Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376(9753): 1658-1669.
27. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008 Nov; 30(11): 2167-2179.
28. Vicki F, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010 Spring; 14(1): 4-10.
29. Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8years in a usual care setting. Am J Manag Care 2008 Jun; 14(6): 388-392.
30. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002 Jul 24-31; 288(4): 462-467.
31. Neuvonen PJ, Niemi M, Backmann JT. Drug interactions with lipid-lowering drugs:mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581.